With July around the corner, investors will be closely tracking the FDA's upcoming decisions on therapies targeting conditions ranging from breast cancer and IgA nephropathy to multiple myeloma, ADHD, and wet AMD.
The following biotech companies are awaiting FDA decisions in July.
AstraZeneca plc (AZN)
The FDA decision on the expanded use of Enhertu as post-neoadjuvant treatment for patients with HER2-positive early breast cancer is due on July 7, 2026.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.